(Q50576761)

15 March 2018

title

Conversion of viramidine to ribavirin in vivo by adenosine deaminase and its inhibition by 2'-deoxycoformycin. (English)

1 reference

15 March 2018

1 reference

Jim Zhen Wu

1

1 reference

15 March 2018

Li-Tain Yeh

series ordinal

2

1 reference

15 March 2018

Chin-Chung Lin

series ordinal

3

1 reference

15 March 2018

Zhi Hong

series ordinal

4

1 reference

15 March 2018

publication date

1 January 2006

1 reference

15 March 2018

Antiviral Chemistry & Chemotherapy

published in

1 reference

15 March 2018

volume

17

1 reference

15 March 2018

issue

1

1 reference

15 March 2018

page(s)

33-39

1 reference

15 March 2018

Tight-binding inhibitors--IV. Inhibition of adenosine deaminases by various inhibitors

cites work

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700105

Inhibition of adenosine deaminase by co-vidarabine and its effect on the metabolic disposition of adenine arabinoside (vidarabine)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700105

Enzyme inhibition titration assay for 2′-deoxycoformycin and its application to the study of the relationship between drug concentration and tissue adenosine deaminase in dogs and rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700105

The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700105

Synthesis and antiviral evaluation of N-carboxamidine-substituted analogues of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine hydrochloride

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700105

Pharmacokinetics and metabolism of [14C]viramidine in rats and cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700105

Viramidine, a prodrug of ribavirin, shows better liver-targeting properties and safety profiles than ribavirin in animals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700105

2'-Deoxycoformycin inhibition of adenosine deaminase in rat brain: in vivo and in vitro analysis of specificity, potency, and enzyme recovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700105

Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700105

Mechanisms of action of ribavirin in antiviral therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700105

Atomic structure of adenosine deaminase complexed with a transition-state analog: understanding catalysis and immunodeficiency mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700105

Synthesis and antiviral activity of 1,2,4-triazole-3-thiocarboxamide and 1,2,4-triazole-3-carboxamidine ribonucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700105

Dual-action mechanism of viramidine functioning as a prodrug and as a catabolic inhibitor for ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700105

Ribavirin, viramidine and adenosine-deaminase-catalysed drug activation: implication for nucleoside prodrug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700105

Activation and deactivation of a broad-spectrum antiviral drug by a single enzyme: adenosine deaminase catalyzes two consecutive deamination reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700105

10.1177/095632020601700105

21 January 2018

Identifiers

DOI

1 reference

15 March 2018

1 reference

15 March 2018